The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Recombinant Interferon Alfa-2b Combined with a Regimen Containing Doxorubicin in Patients with Advanced Follicular Lymphoma
Open accessAbstract
BACKGROUND: Interferon alfa and cytotoxic drugs have synergistic effects in patients with non-Hodgkin's lymphoma. In 1986, we designed a clinical trial to evaluate the benefit of concomitant administration of recombinant interferon alfa with a regimen containing doxorubicin in patients with follicular non-Hodgkin's lymphoma. METHODS: The trial involved 242 patients with advanced low-grade follicular non-Hodgkin's lymphoma selected on the basis of clinical, radiographic, and biologic criteria. All patients were treated with a regimen consisting of cyclophosphamide, doxorubicin, teniposide, and prednisone (CHVP), given monthly for six cycles and then every two months for one year. After randomization, 123 patients also received interferon alfa-2b at a dosage of 5 million units three times weekly for 18 months. The remaining 119 patients received chemotherapy alone. RESULTS: As compared with the patients treated with CHVP only, the patients treated with CHVP plus interferon alfa had a higher overall rate of response (85 percent vs. 69 percent, P = 0.006), a longer median event-free survival (34 months vs. 19 months, P < 0.001), and a higher rate of survival at 3 years (86 percent vs. 69 percent, P = 0.02). Granulocyte toxicity was greater in the patients treated with CHVP plus interferon alfa than in those treated with CHVP alone. There were no treatment-related deaths. Interferon alfa had to be stopped because of toxic effects (fatigue and hepatitis) in 13 patients (11 percent). CONCLUSIONS: The addition of interferon alfa to a regimen containing doxorubicin increased the rate of response, event-free survival, and overall survival in patients with advanced follicular non-Hodgkin's lymphoma, without serious toxicity, although some patients were unable to tolerate the side effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
The Non-Hodgkin's Lymphoma Pathologic Classification Project (1982) · Cancer · doi:10.1002/1097-0142(19820515)49:10<2112::aid-cncr2820491024>3.0.co;2-2 · Cited by 3,059
The Natural History of Initially Untreated Low-Grade Non-Hodgkin's Lymphomas
Horning, S. J., & Rosenberg, S. A. (1984) · New England Journal of Medicine · doi:10.1056/nejm198412063112303 · Cited by 909
CHRONIC COUGH: EOSINOPHILIC BRONCHITIS WITHOUT ASTHMA
Gibson, P. G., Denburg, J., Dolovich, J., Ramsdale, E. H., & Hargreave, F. E. (1989) · The Lancet · doi:10.1016/s0140-6736(89)92801-8 · Cited by 665
Prognostic Factors for Survival in Patients With Inoperable Lung Cancer 2
(1980) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/65.1.25 · Cited by 564
Follicular lymphoma: prognostic factors for response and survival.
Gallagher, C. J., Gregory, W. M., Jones, A. E., Stansfeld, A. G., Richards, M. A., Dhaliwal, H. S., Malpas, J. S., & Lister, T. A. (1986) · Journal of Clinical Oncology · doi:10.1200/jco.1986.4.10.1470 · Cited by 425
Wadler, S., & Schwartz, E. L. (1990) · PubMed · Cited by 342
Treatment of Advanced Non-Hodgkin's Lymphoma with Recombinant Leukocyte a Interferon
Foon, K. A., Sherwin, S. A., Abrams, P. G., Longo, D. L., Fer, M. F., Stevenson, H. C., Ochs, J. J., Bottino, G. C., Schoenberger, C. S., Zeffren, J., et al. (1984) · New England Journal of Medicine · doi:10.1056/nejm198411013111803 · Cited by 274
Interferon Alfa Combined with Cytotoxic Chemotherapy for Patients with Non-Hodgkin's Lymphoma
Smalley, R. V., Andersen, J. W., Hawkins, M. J., Bhide, V., O'Connell, M. J., Oken, M. M., & Borden, E. C. (1992) · New England Journal of Medicine · doi:10.1056/nejm199211053271902 · Cited by 173
Cited by
Harris, N. L., Jaffe, E. S., Diebold, J., Flandrin, G., Muller-Hermelink, H. K., Vardiman, J., Lister, T. A., & Bloomfield, C. D. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.12.3835 · Cited by 3,267
Protein Therapeutics: A Summary and Pharmacological Classification
Leader, B., Baca, Q. J., & Golan, D. E. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2399 · Cited by 2,161
Cytokines in clinical cancer immunotherapy
Berraondo, P., Sanmamed, M. F., Ochoa, M. C., Etxeberria, I., Aznar, M. A., Pérez-Gracia, J. L., Rodríguez-Ruiz, M. E., Ponz-Sarvise, M., Castañón, E., & Melero, I. (2019) · British Journal of Cancer · doi:10.1038/s41416-018-0328-y · Cited by 1,205
131I-Tositumomab Therapy as Initial Treatment for Follicular Lymphoma
Kaminski, M. S., Tuck, M., Estes, J., Kolstad, A., Ross, C. W., Zasadny, K., Regan, D., Kison, P., Fisher, S., Kroll, S., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa041511 · Cited by 716
Cytokine therapeutics: lessons from interferonalpha.
Gutterman, J. U. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.4.1198 · Cited by 703
Metadata
- Authors
- Solal-Celigny, P., Lepage, E., Brousse, N., Reyes, F., Haioun, C., Leporrier, M., Peuchmaur, M., Bosly, A., Parlier, Y., Brice, P., Coiffier, B., & Gisselbrecht, C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 1993-11-25
- Volume
- 329
- Issue
- 22
- Pages
- 1608-1614
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2093312029
- Cited by
- 268
- References
- 13
- FWCI
- 9.70
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Recombinant Interferon Alfa-2b Combined with a Regimen Containing Doxorubicin in Patients with Advanced Follicular Lymphoma. https://app.cochat.ai/papers/10.1056/nejm199311253292203
- The paper
- Solal-Celigny, P., Lepage, E., Brousse, N., Reyes, F., Haioun, C., Leporrier, M., Peuchmaur, M., Bosly, A., Parlier, Y., Brice, P., Coiffier, B., & Gisselbrecht, C. (1993). Recombinant Interferon Alfa-2b Combined with a Regimen Containing Doxorubicin in Patients with Advanced Follicular Lymphoma. New England Journal of Medicine. https://doi.org/10.1056/nejm199311253292203
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.